3 Dividend Stocks That Will Be Winners From a Coronavirus Vaccine
The COVID-19 pandemic has had a devastating impact on society and the economy this year. Some companies closed their doors for good, while many others struggled to make it through by cutting expenses like dividends.
However, after months of waiting, we received several doses of good news over the past couple of weeks as data on two leading
The catalyst needed to fuel a recovery in demand
The company only generated $491 million of cash during the
It's not generating enough cash right now because it's only using about three-quarters of its refining capacity due to weak demand and low margins. As a result, its refining operations lost nearly $1 billion in the third quarter, which it partially offset with its midstream, marketing, and chemical businesses. However, a widely available vaccine would give people the confidence to travel again, boosting gasoline consumption and refining profitability. That would enable Phillips 66 to generate more cash and put its dividend on a firmer foundation. Moreover, the company would likely be able to resume share buybacks, giving its stock -- which is still down nearly 50% this year even after its
When things get back to normal
Third-quarter earnings, for example, fell nearly 6% year over year. That's not terrible, but if a COVID-19 vaccine can help to get global growth back on track, 3M would likely see earnings turn higher. That's not a shocking statement, given the
But when a vaccine does get developed, approved, and distributed, virtually all of 3M's businesses are likely to benefit from a world that will be eager to get back to normal. Sure, demand for some products (like N95 masks) might fall off, but the strength from the rest of its industrial portfolio should power ahead. Meanwhile, if you act now, you can collect 3M's historically high 3.4% yield while you watch as the medical industry successfully develops new vaccines.
Returning to growth and margin expansion
Management doesn't expect a rapid recovery in aerospace but did say that low interest rates, fiscal stimulus, and a vaccine in early 2021 would likely help Honeywell return to growth and margin expansion. Another benefit of a vaccine is that it would likely lead to increased demand for fuels used in transportation and industrial processes, which could help Honeywell UOP.
Honeywell would be a big winner from a coronavirus vaccine, but it also has the financial strength to weather a prolonged economic slowdown or a slower-than-expected vaccine rollout. The company has very little debt and plenty of cash to pay expenses, make investments, and cover its dividend, which yields 1.8%. Honeywell is an attractive investment in that its business would improve from a vaccine, but it is diversified enough to generate sizable cash flow and earnings even without one.
10 stocks we like better than 3M
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the
*Stock Advisor returns as of October 20, 2020